Under President Donald Trump's proposed 2018 budget, drug and device companies would have to pay almost twice as much for the Food and Drug Administration to review products, reports Reuters.
Here are three things to know.
1. The proposed budget includes $2 billion in fees for the FDA to collect from the drug and device industry, which is almost double the allotted amount in the 2017 budget, according to the report.
2. The Trump administration said industries that benefit from FDA approvals "can and should pay for their share," amid such a constrained budget environment, reports Reuters. In return, the administration vowed to implement measures to speed up approvals, although specific examples were not included in the budget.
3. The FDA has charged companies for regulatory review since 1992. Most of the fees the agency collects come from reviewing new drugs. The agency brought in an estimated $866 million for reviewing new brand name drugs and about $324 million for reviewing generic drugs in 2017, according to the report.
More articles on supply chain:
Patients often skip, delay or ration cancer treatments due to high drug costs: 5 takeaways
7 things to know about Dr. Scott Gottlieb's relationship with the drug industry
Mylan settles biosimilar patent dispute with Roche: 4 things to know